Alnylam Pharmaceuticals, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Alnylam is a biopharmaceutical company focused on discovering and developing RNA interference therapeutics to treat genetic illnesses.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Alnylam Pharmaceuticals, Inc., though not profitable, operates in a manner that is a net positive for humanity, primarily due to Healthcare R&D ($24.7 B), Pharmaceuticals ($2.0 B), and Medical Services ($41.8 M). Positive value from Healthcare R&D, Pharmaceuticals, and Medical Services is linked to an estimate of 510,000 additional years lived by people worldwide. The Humankind Value of this company can improve with reductions in Greenhouse Gases (-$44.5 M) and Air Pollution (-$5.6 M). Healthcare R&D, Pharmaceuticals, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities. Medical Services is largely a consequence of the actions of supply chain partners.